Drug repurposing to treat Viruses: COVID-19

Drug repurposing is a methodology for making more value from an existing drug by targeting diseases by focusing on infections other than that for which it was initially proposed, For instance, teicoplanin, oritavancin, dalbavancin and monensin are affirmed antibiotics that have been appeared to inhibit corona- and other viruses in the research facility. The researchers reviewed information on the discovery and development of wide-spectrum antiviral agents (BSAAs), which are drugs that target viruses from two or more different viral families. They condensed what they found for 120 drugs that had just been demonstrated to be ok for people use and made a database, which is uninhibitedly available Thirty-one of these were found by the researchers to be possible candidates for prophylaxis and treatment of the COVID-19 infections. The researchers also found that clinical investigations have recently begun of five possible drug candidates to treat the virus that causes COVID-19.


    Related Conference of Drug repurposing to treat Viruses: COVID-19

    October 31-01, 2024

    8th International Conference on Internal Medicine

    Amsterdam, Netherlands
    November 22-23, 2024

    4th International Conference on Medical Research and Development

    Aix-en-Provence, France
    November 25-26, 2024

    10th World Congress on Anesthesia and Critical Care

    Paris, France
    June 24-25, 2025

    3rd Global Summit on HIV-AIDS and STDs

    Chicago, USA
    August 07-08, 2025

    12th World Summit on Epilepsy and Bipolar Disorders

    Paris, France

    Drug repurposing to treat Viruses: COVID-19 Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in